Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation

Background Smoking is an important risk factor for several diseases, including different cancers, lung diseases and cardiovascular diseases. About 21% of the Norwegian population are daily smokers. Interventions for smoking cessation are normally divided into counselling and drug treatment support....

Full description

Main Authors: Hagen, Gunhild, Wisløff, Torbjørn (Author), Klemp, Marianne (Author)
Corporate Author: Nasjonalt kunnskapssenter for helsetjenesten
Format: eBook
Language:English
Published: Oslo Norwegian Knowledge Centre for the Health Services 2010, May 2010
Series:Health economic evaluation
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Background Smoking is an important risk factor for several diseases, including different cancers, lung diseases and cardiovascular diseases. About 21% of the Norwegian population are daily smokers. Interventions for smoking cessation are normally divided into counselling and drug treatment support. In Norway, two prescription drugs are available for use in smoking cessation; varenicline (Champix (r) or Chantix (r)) and bupropion (Zyban (r)). In addition, several options for nicotine replacement therapy are available, such as nicotine-gum, patches and lozenges. Commision We were commissioned to evaluate the cost-effectiveness of drugs for smoking cessation in a Norwegian setting. The economic evaluation will inform the revised treatment guideline for smoking cessation in primary care. Main findings1. Compared to no treatment, nicotine replacement therapy, bupropion and varenicline can all be considered cost-effective.2. When the drugs are evaluated relative to each other, varenicline is the most cost-effective alternative
Physical Description:1 PDF file (48 pages) illustrations
ISBN:9788281213418